The 2024 Don’t Bank on the Bomb analysis identifies 260 banks, pension funds, insurance companies and other financial institutions with significant finance or investment relations with the 24 main nuclear weapons producers.
By Alejandra Muñoz, ICAN
The number of Institutions with significant financial exposure to companies involved in the nuclear weapons industry has dropped by a quarter since the Treaty on the Prohibition of Nuclear Weapons came into force in 2021 according to “At Great Cost: The companies building nuclear weapons and their financiers” a new report from the International Campaign to Abolish Nuclear Weapons (ICAN) and PAX. Read more about the significance of this trend here.

All nine nuclear-armed states are investing in their nuclear arsenals. Several of these countries contract the private sector to manufacture and service their nuclear weapons; the 24 most significant of these companies are identified in this report. The most significant contracts for nuclear weapons related work went to Northrop Grumman, General Dynamics, BAE Systems, Boeing, Leonardo, Lockheed Martin and RTX.
The report should load below, or download the PDF here.
Recent Posts
Washington, DC, Residents Protest Against Trump
September 7, 2025
Take Action Now Several thousand protesters march to oppose Trump’s troop deployment Justice Department data shows violent crime at 30-year low…
‘Shameful Assault on Human Rights’: Trump Sanctions Palestinian Orgs That Called for UN to Investigate Israeli War Crimes
September 6, 2025
Take Action Now The former executive director of Human Rights Watch said Trump’s “answer to Israeli atrocities is to censor reporting on…
Hegseth Doesn’t Rule Out Regime Change In Venezuela, Suggests More U.S. Strikes On Boats Are Coming
September 5, 2025
Take Action Now When asked if the goal was regime change in Venezuela, Hegseth said that was a “presidential decision” and added that “we’re prepared…
Secretary Kennedy Doesn’t Care About Long COVID Patients
September 5, 2025
Take Action Now Reckless funding cuts have dealt a significant blow to ongoing research, derailing NIH-funded clinical trials on antivirals and…